Using small molecules to degrade important cancer-related proteins
Degrading therapeutically important kinases using small molecules
This study is looking at new ways to help cancer patients by creating small molecules that can help get rid of certain proteins that help cancer cells grow and survive, which could lead to better treatments that work even when other therapies stop being effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11019832 on NIH RePORTER |
What this research studies
This research focuses on developing small molecules that can induce the degradation of specific kinases involved in cancer signaling pathways. By targeting these kinases, which are often responsible for cancer cell growth and survival, the research aims to overcome resistance that tumors develop against traditional kinase inhibitors. The approach utilizes the ubiquitin-proteasome pathway to effectively eliminate these proteins from cancer cells, potentially leading to more effective cancer treatments. Patients may benefit from new therapies that are less likely to encounter resistance compared to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer that are driven by oncogenic kinases.
Not a fit: Patients whose cancers are not driven by kinase activity or who have already exhausted all available treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that prevent or overcome resistance in tumors.
How similar studies have performed: Other research has shown promise in targeting kinases for degradation, indicating that this approach could be a viable and innovative treatment strategy.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Gray, Nathanael Schiander — Stanford University
- Study coordinator: Gray, Nathanael Schiander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.